{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(8)"],"submitter":["Ponnaiah M"],"pubmed_abstract":["Background
In the ongoing COVID-19 pandemic, an increased incidence of ROCM was noted in India among those infected with COVID. We determined risk factors for rhino-orbito-cerebral mucormycosis (ROCM) post Coronavirus disease 2019 (COVID-19) among those never and ever hospitalized for COVID-19 separately through a multicentric, hospital-based, unmatched case-control study across India.Methods
We defined cases and controls as those with and without post-COVID ROCM, respectively. We compared their socio-demographics, co-morbidities, steroid use, glycaemic status, and practices. We calculated crude and adjusted odds ratio (AOR) with 95% confidence intervals (CI) through logistic regression. The covariates with a p-value for crude OR of less than 0·20 were considered for the re"],"journal":["PloS one"],"pagination":["e0272042"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9359565"],"repository":["biostudies-literature"],"pubmed_title":["Hyperglycemia and steroid use increase the risk of rhino-orbito-cerebral mucormycosis regardless of COVID-19 hospitalization: Case-control study, India."],"pmcid":["PMC9359565"],"pubmed_authors":["Bhojani D","Chaudhary N","Kavi A","Dhodapkar R","Bhavana K","Palaninathan K","Rathinavel A","R V","Balaji NK","Jaisankar S","Ray S","Sheikh KM","Samadhiya M","Bhatnagar T","Sarkar S","Ganesan S","Pillai N","Singh R","Gupta N","Mallya SD","Ravi D","Banumathi K","Karuppiah M","Selvaraj K","Vaidya S","Hegde R","B H S","Sumathi V","Kumar GCP","K G","Kankaria A","Sharma V","Priya S","Singh SRB","Harugop AS","Thulasingam M","Kar SS","Karthikeyan S","Ramesh D","Kasthuri N","Bellad SA","Aggarwal R","Ramalingam S","Pillai VM","Saini V","Pujary K","Pandian RD","Nair PP","S PK","Dube S","Murali A","Kumar SS","Singh CM","Ponnaiah M","Saxena RS","Deepthi P","Soni K","Rizwan SA","Murhekar M","Arulsundareshkumar","Lakshmanan S","Khichar S","Patel MN","Alexander A","Bhatnagar A","Ch Toi P","Goyal A","Majella MG","Shristava V","Prasad HM","Shantaraman K","Raj A","Ballala K","Bharti B","Garg MK","Mishra N","Nissar SP","Kadhiravan T"],"additional_accession":[]},"is_claimable":false,"name":"Hyperglycemia and steroid use increase the risk of rhino-orbito-cerebral mucormycosis regardless of COVID-19 hospitalization: Case-control study, India.","description":"Background
In the ongoing COVID-19 pandemic, an increased incidence of ROCM was noted in India among those infected with COVID. We determined risk factors for rhino-orbito-cerebral mucormycosis (ROCM) post Coronavirus disease 2019 (COVID-19) among those never and ever hospitalized for COVID-19 separately through a multicentric, hospital-based, unmatched case-control study across India.Methods
We defined cases and controls as those with and without post-COVID ROCM, respectively. We compared their socio-demographics, co-morbidities, steroid use, glycaemic status, and practices. We calculated crude and adjusted odds ratio (AOR) with 95% confidence intervals (CI) through logistic regression. The covariates with a p-value for crude OR of less than 0·20 were considered for the re","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T07:15:37.612Z","creation":"2025-04-04T07:15:37.612Z"},"accession":"S-EPMC9359565","cross_references":{"pubmed":["35939442"],"doi":["10.1371/journal.pone.0272042"]}}